Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
delNS (Prostate Cancer)
- Development stage
- Preclinical
- Lead developer
- BlueSky Immunotherapies
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous, Intramuscular, Intratumoral
01
Overview
delNS (Prostate Cancer) is a preclinical-stage therapeutic vaccine being developed by BlueSky Immunotherapies for the treatment of aggressive and castration-resistant prostate cancer. The vaccine utilizes BlueSky's proprietary delNS platform, which consists of an influenza A virus vector with a deleted NS1 gene. This modification renders the virus replication-deficient in normal cells while allowing it to induce high levels of interferon and activate a potent, multi-faceted immune response. In this specific candidate, the delNS vector is engineered to deliver prostate-specific tumor antigens directly to the immune system, aiming to elicit a robust T-cell mediated anti-tumor response against advanced prostate malignancies.
- Other names
- BlueSky prostate cancer vaccine
Beyond the preview
Go deeper on delNS (Prostate Cancer).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on delNS (Prostate Cancer).